➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Merck
Medtronic
Boehringer Ingelheim
Dow

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,126,931

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,126,931 protect, and when does it expire?

Patent 9,126,931 protects ALECENSA and is included in one NDA.

This patent has seventy patent family members in thirty-seven countries.

Summary for Patent: 9,126,931
Title:Tetracyclic compound
Abstract: A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: ##STR00001## (meanings of the symbols that are included in the formula are as given in the specification).
Inventor(s): Kinoshita; Kazutomo (Kanagawa, JP), Asoh; Kohsuke (Kanagawa, JP), Furuichi; Noriyuki (Kanagawa, JP), Ito; Toshiya (Kanagawa, JP), Kawada; Hatsuo (Kanagawa, JP), Ishii; Nobuya (Kanagawa, JP), Sakamoto; Hiroshi (Kanagawa, JP), Hong; WooSang (Gyeonggi-do, KR), Park; MinJeong (Gyeonggi-do, KR), Ono; Yoshiyuki (Shizuoka, JP), Kato; Yasuharu (Shizuoka, JP), Morikami; Kenji (Shizuoka, JP), Emura; Takashi (Shizuoka, JP), Oikawa; Nobuhiro (Kanagawa, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:13/377,300
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 9,126,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,126,931

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2009-139691Jun 10, 2009
PCT Information
PCT FiledJune 09, 2010PCT Application Number:PCT/JP2010/059785
PCT Publication Date:December 16, 2010PCT Publication Number: WO2010/143664

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Merck
Colorcon
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.